Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors

Biomaterials

Volumn 32, Issue 35, 2011, Pages 9457-9469

  Jiang, Xinyi ^a,b   Sha, Xianyi ^a,b   Xin, Hongliang ^a,b   Chen, Liangcen ^a,b   Gao, Xihui ^a,b   Wang, Xiao ^a,b   Law, Kitki ^a,b,c   Gu, Jijin ^a,b   Chen, Yanzuo ^a,b   Jiang, Ye ^a,b   Ren, Xiaoqing ^a,b   Ren, Qiuyue ^a,b   Fang, Xiaoling ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Cyclic RGD; Integrin protein; Nanoparticles; Paclitaxel; PEG PTMC

Indexed keywords

ACTIVE TARGETING; AMPHIPHILIC DIBLOCK COPOLYMERS; CANCER CELLS; CELL APOPTOSIS; CELL-CYCLE ARREST; CELLULAR UPTAKE; CHEMOTHERAPEUTIC AGENTS; CYCLIC RGD; FLUORESCENT IMAGING; FUNCTIONALIZED; HIGH AFFINITY; HIGH SPECIFICITY; IN-VITRO; IN-VIVO; INTEGRINS; MICELLAR NANOPARTICLES; MULTI-SPECTRAL; PACLITAXEL; PACLITAXEL DELIVERY; PEG-PTMC; PHARMACOKINETIC STUDIES; POLY(TRIMETHYLENE CARBONATE); RGD PEPTIDE; TUMOR CELLS;

BIOCHEMISTRY; BLOCK COPOLYMERS; CARBONATION; CELL DEATH; ETHYLENE; GLYCOLS; MOLECULAR BIOLOGY; NANOPARTICLES; PEPTIDES; POLYETHYLENE OXIDES; POLYMERS; RING OPENING POLYMERIZATION; TUMORS; ZETA POTENTIAL;

POLYETHYLENE GLYCOLS;

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; NANOPARTICLE; PACLITAXEL; PEGYLATED POLY(TRIMETHYLENE CARBONATE) NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SPECIFICITY; DRUG TARGETING; EMULSION; ENDOCYTOSIS; EVAPORATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; RING OPENING METATHESIS POLYMERIZATION; ZETA POTENTIAL;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; COUMARINS; DIOXANES; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PARTICLE SIZE; PEPTIDES; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUBCELLULAR FRACTIONS; THIAZOLES;

RATTUS;

EID: 80053592196     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.08.055     Document Type: Article

References (37)

1. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006, 5:1909-1917.
2. Williams J., Lansdown R., Sweitzer R., Romanowski M., LaBell R., Ramaswami R., et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release 2003, 91:167-172.
3. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. McCarthy T.D., Karellas P., Henderson S.A., Giannis M., O'Keefe D.F., Heery G., et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005, 2:312-318.
5. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
6. Shukla R., Thomas T.P., Peters J.L., Desai A.M., Kukowska-Latallo J., Patri A.K., et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006, 17:1109-1115.
7. Yang M., Li H., Javadi A., Gong S. Multifunctional mesoporous silica nanoparticles as labels for the preparation of ultrasensitive electrochemical immunosensors. Biomaterials 2010, 31:3281-3286.
8. Liu Z., Tabakman S.M., Chen Z., Dai H. Preparation of carbon nanotube bioconjugates for biomedical applications. Nat Protoc 2009, 4:1372-1382.
9. Akao T., Kimura T., Hirofuji Y.S., Matsunaga K., Imayoshi R., Nagao J., et al. A poly(gamma-glutamic acid)-amphiphile complex as a novel nanovehicle for drug delivery system. J Drug Target 2010, 18:550-556.
10. Tomas S., Milanesi L. Hydrophobically self-assembled nanoparticles as molecular receptors in water. J Am Chem Soc 2009, 131:6618-6623.
11. Chavez J.L., Wong J.L., Duran R.S. Core-shell nanoparticles: characterization and study of their use for the encapsulation of hydrophobic fluorescent dyes. Langmuir 2008, 24:2064-2071.
12. Yang X., Zhang Q., Wang Y., Chen H., Zhang H., Gao F., et al. Self-aggregated nanoparticles from methoxy poly(ethylene glycol)-modified chitosan: synthesis; characterization; aggregation and methotrexate release in vitro. Colloids Surf B Biointerfaces 2008, 61:125-131.
13. Zhang Z., Kuijer R., Bulstra S.K., Grijpma D.W., Feijen J. The in vivo and in vitro degradation behavior of poly(trimethylene carbonate). Biomaterials 2006, 27:1741-1748.
14. Han J., Chen T.X., Branford-White C.J., Zhu L.M. Electrospun shikonin-loaded PCL/PTMC composite fiber mats with potential biomedical applications. Int J Pharm 2009, 382:215-221.
15. Pego A.P., Van Luyn M.J., Brouwer L.A., van Wachem P.B., Poot A.A., Grijpma D.W., et al. In vivo behavior of poly(1,3-trimethylene carbonate) and copolymers of 1,3-trimethylene carbonate with D, L-lactide or epsilon-caprolactone: degradation and tissue response. J Biomed Mater Res A 2003, 67:1044-1054.
16. Zhu K.J., Hendren R.W., Jensen K., Pitt C.G. Synthesis, properties, and biodegradation of poly(1,3-trimethylene carbonate). Macromolecules 1991, 24:1736-1740.
17. Mao S., Shuai X., Unger F., Wittmar M., Xie X., Kissel T. Synthesis, characterization and cytotoxicity of poly(ethylene glycol)-graft-trimethyl chitosan block copolymers. Biomaterials 2005, 26:6343-6356.
18. Ogris M., Brunner S., Schuller S., Kircheis R., Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 1999, 6:595-605.
19. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22:405-417.
20. Cai W., Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006, 6:407-428.
21. Eldar-Boock A., Miller K., Sanchis J., Lupu R., Vicent M.J., Satchi-Fainaro R. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 2011, 32:3862-3874.
22. Chen W., Jarzyna P.A., van Tilborg G.A., Nguyen V.A., Cormode D.P., Klink A., et al. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 2010, 24:1689-1699.
23. Connelly J.T., Garcia A.J., Levenston M.E. Inhibition of in vitro chondrogenesis in RGD-modified three-dimensional alginate gels. Biomaterials 2007, 28:1071-1083.
24. Amiji M.M., Lai P.K., Shenoy D.B., Rao M. Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation. Pharm Dev Technol 2002, 7:195-202.
25. Geisler J.P., Linnemeier G.C., Thomas A.J., Manahan K.J. Extreme drug resistance is common after prior exposure to paclitaxel. Gynecol Oncol 2007, 106:538-540.
26. Ganta S., Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009, 6:928-939.
27. Musacchio T., Laquintana V., Latrofa A., Trapani G., Torchilin V.P. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm 2009, 6:468-479.
28. Zhang Z., Grijpma D.W., Feijen J. Thermo-sensitive transition of monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) films to micellar-like nanoparticles. J Control Release 2006, 112:57-63.
29. Zhang Y., Zhuo R.X. Synthesis and drug release behavior of poly (trimethylene carbonate)-poly (ethylene glycol)-poly (trimethylene carbonate) nanoparticles. Biomaterials 2005, 26:2089-2094.
30. Zhang Y., Zhang Q., Zha L., Yang W., Wang C., Jiang X., et al. Preparation, characterization and application of pyrene-loaded methoxy poly (ethylene glycol)̇Cpoly (lactic acid) copolymer nanoparticles. Colloid Polym Sci 2004, 282:1323-1328.
31. Martel V., Vignoud L., Dupe S., Frachet P., Block M.R., Albigès-Rizo C. Talin controls the exit of the integrin alpha 5 beta 1 from an early compartment of the secretory pathway. J Cell Sci 2000, 113:1951.
32. Larkin D., Murphy D., Reilly D.F., Cahill M., Sattler E., Harriott P., et al. ICln, a novel integrin αvβ3-associated protein, functionally regulates platelet activation. J Biol Chem 2004, 27(α9):27286.
33. Liebmann J., Cook J.A., Lipschultz C., Teague D., Fisher J., Mitchell J.B. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol(R)) in human tumor cell lines. Cancer Chemotherapy Pharmacology 1994, 33:331-339.
34. Costa M.A., Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation 2005, 111:2257.
35. Ng S.S.W., Tsao M.S., Chow S., Hedley D.W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Research 2000, 60:5451.
36. Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995, 17:31-48.
37. Zhang Y., Kohler N., Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002, 23:1553-1561.